Form D · Biotechnology
Goldenrod Therapeutics, Inc.
Houston, TX · CIK 0002127885
Offering snapshot reported Jun 3, 2026 · SEC filing
- Reported sold
- $3.25M Offering amount: $6.51M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $100K Reported outside-investor minimum
- First sale
- May 26, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 3, 2026 | Initial | $3,245,355 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-586108
Source: Form D, filed Jun 3, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Thomas Brenninkmeijer | Director |
| Dev Chatterjee | Executive |
| Leo Linbeck Iii | Director |
| Leo Linbeck Iv | Executive |
| Atul Varadhachary | Director, Executive |
| Mark Worscheh | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3900 Essex Lane, Suite 575
Houston, TX, 77027
Houston, TX, 77027